Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: A systematic review and meta-analysis

International Urology and Nephrology

Volumn 46, Issue 10, 2014, Pages 2035-2044

  Su, Liya ^a,b   Tam, Ngalei ^a,c   Deng, Ronghai ^a   Chen, Philip ^d   Li, Haibo ^b   Wu, Linwei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Calcineurin inhibitor; Everolimus; Meta analysis; Renal transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADVERSE OUTCOME; ANEMIA; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DEATH; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MOUTH ULCER; PROTEINURIA; REVIEW; RISK REDUCTION; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; GRAFT REJECTION; KIDNEY FUNCTION TEST; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CALCINEURIN INHIBITORS; CYCLOSPORINE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIROLIMUS;

EID: 84907594384     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-014-0783-1     Document Type: Review

References (50)

1. Calne RY, White DJ, Thiru S et al (1978) Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2(8104-8105):1323-1327
2. Chapman JR, Valantine H, Albanell J et al (2007) Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 39(10):2937-2950
3. Nankivell BJ, Borrows RJ, Fung CL et al (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349(24):2326-2333
4. Campbell S, McDonald S, Chang S et al (2011) ANZDATA registry. The 30th annual report. Ch8Transplantation. http://www.anzdata.org.au/anzdata/AnzdataReport/30thReport
5. Watanabe R, Wei L, Huang J (2011) mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 52(4):497-500
6. Holdaas H, Midtvedt K, Asberg A (2012) A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf 11(6):1013-1022
7. Schuurman HJ, Cottens S, Fuchs S et al (1997) SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64(1):32-35
8. Lutz J, Zou H, Liu S et al (2003) Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 76(3):508-515
9. Koch M, Mengel M, Poehnert D et al (2007) Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplantation 83(4):498-505
10. Stypmann J, Engelen MA, Eckernkemper S et al (2011) Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Munster. Transplant Proc 43(5):1847-1852
11. Gullestad L, Iversen M, Mortensen SA et al (2010) Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 89(7):864-872
12. Masetti M, Montalti R, Rompianesi G et al (2010) Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 10(10):2252-2262
13. Kamar N, Allard J, Ribes D et al (2005) Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. Clin Nephrol 63(2):80-86
14. Rostaing L, Kamar N (2010) mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 23(2):133-142
15. Peddi VR, Wiseman A, Chavin K et al (2013) Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando) 27(4):97-107
16. Webster AC, Lee VW, Chapman JR et al (2006) Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81(9):1234-1248
17. Novartis Pharmaceuticals (2010) Zortress (everolimus) [package insert]. Novartis Pharmaceuticals, East Hanover, NJ. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e082a024-7850-400b-a5c2-2a140612562a
18. Gabardi S, Baroletti SA (2010) Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 30(10):1044-1056
19. Bertoni E, Larti A, Rosso G et al (2011) Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. J Nephrol 24(5):613-618
20. Budde K, Becker T, Arns W et al (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768):837-847
21. Cibrik D, Silva HJ, Vathsala A et al (2013) Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 95(7):933-942
22. Holdaas H, Rostaing L, Seron D et al (2011) Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 92(4):410-418
23. Mjornstedt L, Sorensen SS, von Zur MB et al (2012) Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 12(10):2744-2753
24. Santos SM, Carlos CM, Cabanayan-Casasola CB et al (2012) Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience. Transplant Proc 44(1):154-160
25. Chadban SJ, Eris JM, Kanellis J et al (2013) A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int 27:302-311
26. Budde K, Lehner F, Sommerer C et al (2012) Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant 12(6):1528-1540
27. Nashan B, Curtis J, Ponticelli C et al (2004) Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78(9):1332-1340
28. Salvadori M, Rosati A, Bock A et al (2006) Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation 81(2):202-206
29. Helal I, Abderrahim E, Ben HF et al (2009) The first year renal function as a predictor of long-term graft survival after kidney transplantation. Transplant Proc 41(2):648-650
30. Resende L, Guerra J, Santana A et al (2009) First year renal function as a predictor of kidney allograft outcome. Transplant Proc 41(3):846-848
31. Letavernier E, Legendre C (2008) mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 22(2):125-130
32. Diekmann F, Budde K, Oppenheimer F et al (2004) Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4(11):1869-1875
33. Oroszlan M, Bieri M, Ligeti N et al (2010) Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 23(3):125-132
34. Stallone G, Infante B, Grandaliano G et al (2009) Management of side effects of sirolimus therapy. Transplantation 87(8 Suppl):S23-S26
35. Kaplan B, Qazi Y, Wellen JR (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). doi: 10.1016/j.trre.2014.03.002
36. Sellares J, de Freitas DG, Mengel M et al (2011) Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant 11(3):489-499
37. Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357(25):2562-2575
38. Flechner SM, Glyda M, Cockfield S et al (2011) The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 11(8):1633-1644
39. Asberg A, Midtvedt K, Line PD et al (2006) Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 82(1):62-68
40. Vitko S, Margreiter R, Weimar W et al (2004) Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78(10):1532-1540
41. Havenith SH, Yong SL, van Donselaar-van DPK et al (2013) Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation 95(1):184-191
42. Sagedal S, Nordal KP, Hartmann A et al (2002) The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2(9):850-856
43. Ojo AO (2006) Cardiovascular complications after renal transplantation and their prevention. Transplantation 82(5):603-611
44. Eisen H (2006) Long-term cardiovascular risk in transplantation-insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 21(Suppl 3):i9-i13
45. Lv C, Chen M, Xu M et al (2014) Influencing factors of new-onset diabetes after a renal transplant and their effects on complications and survival rate. PLoS One 9(6):e99406
46. Mahe E, Morelon E, Lechaton S et al (2005) Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79(4):476-482
47. Ponticelli C (2014) The pros and the cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol 10(2):295-305
48. Groth CG, Backman L, Morales JM et al (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67(7):1036-1042
49. Glotz D, Charpentier B, Abramovicz D et al (2010) Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 89(12):1511-1517
50. Lebranchu Y, Snanoudj R, Toupance O et al (2012) Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study. Am J Transplant 12(7):1801-1810